https://www.selleckchem.com/products/c188-9.html
After a legally mandated, decades-long global arrest of research on psychedelic drugs, investigation of psychedelics in the context of psychiatric disorders is yielding exciting results. Outcomes of neuroscience and clinical research into 5-Hydroxytryptamine 2A (5-HT2A) receptor agonists, such as psilocybin, show promise for addressing a range of serious disorders, including depression and addiction. With recent advances in both gene editing and stem cell biology, the promise of cellular therapies is now closer than ever. Clinical trials
Like
Comment
Share
